Published in J Clin Endocrinol Metab on March 01, 2003
Vascular calcification: pathobiology of a multifaceted disease. Circulation (2008) 3.64
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol (2007) 2.02
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
Vascular calcification in chronic kidney disease. J Bone Miner Metab (2006) 1.42
Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int (2006) 1.39
The link between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab (2008) 1.08
(Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk; a systematic review of the association between cardiovascular disease and osteoporosis. Arthritis Res Ther (2011) 1.07
Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int (2008) 1.06
Adverse effects of hyperlipidemia on bone regeneration and strength. J Bone Miner Res (2012) 1.01
Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis (2007) 1.00
An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol (2006) 1.00
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag (2012) 0.97
RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-α. J Vasc Res (2012) 0.96
The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification. Circ Res (2011) 0.96
Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol (2012) 0.94
Cholesterol in vascular and valvular calcification. Circulation (2001) 0.92
Increased bone resorption is associated with increased risk of cardiovascular events in men: the MINOS study. J Bone Miner Res (2009) 0.92
TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One (2013) 0.91
Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol (2010) 0.89
The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol (2007) 0.87
Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes. Diabetes Care (2013) 0.87
Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Hum Genet (2012) 0.85
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther (2008) 0.84
Regulatory circuits controlling vascular cell calcification. Cell Mol Life Sci (2012) 0.83
Osteoprotegerin as a marker of atherosclerosis in diabetic patients. Int J Endocrinol (2013) 0.82
Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J (2007) 0.82
Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6. J Vasc Res (2014) 0.81
Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin. ISRN AIDS (2013) 0.80
The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review. Wien Med Wochenschr (2011) 0.80
Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer (2015) 0.80
Enhanced mineralization potential of vascular cells from SM22α-Rankl (tg) mice. Calcif Tissue Int (2012) 0.79
Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients. Genet Mol Biol (2013) 0.79
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease. Biomed Res Int (2016) 0.79
Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension. Am J Hypertens (2010) 0.78
Clinical, microbiological, and salivary biomarker profiles of dental implant patients with type 2 diabetes. Clin Oral Implants Res (2013) 0.78
Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol (2016) 0.78
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis. Mediators Inflamm (2014) 0.78
Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis. Mediators Inflamm (2014) 0.77
Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease. Chin Med J (Engl) (2016) 0.77
Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc Disord (2015) 0.77
Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms. PLoS One (2016) 0.77
Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Braz J Med Biol Res (2014) 0.77
Skeleton and glucose metabolism: a bone-pancreas loop. Int J Endocrinol (2015) 0.76
Polymorphisms in three genes are associated with hemorrhagic stroke. Brain Behav (2015) 0.75
Osteoprotegerin levels in ST-elevation myocardial infarction: Temporal profile and association with myocardial injury and left ventricular function. PLoS One (2017) 0.75
Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children. Iran Red Crescent Med J (2016) 0.75
Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis. Clin Rheumatol (2016) 0.75
Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit (2012) 0.75
Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int J Mol Sci (2016) 0.75
Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus. Lupus (2016) 0.75
Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. Sci Rep (2015) 0.75
Serum osteoprotegerin and renal function in the general population: the Tromsø Study. Clin Kidney J (2016) 0.75
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
Osteoporosis: now and the future. Lancet (2011) 5.81
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2013) 3.50
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Invest (2013) 2.48
The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol (2012) 2.48
Ruling out coronary artery disease in primary care: development and validation of a simple prediction rule. CMAJ (2010) 2.37
Athlete's heart or hypertrophic cardiomyopathy? Clin Res Cardiol (2008) 2.32
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor. Clin Chem (2004) 2.23
Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J (2005) 2.11
Incidence rates and predictors of major and minor depression in patients with heart failure. Int J Cardiol (2012) 2.05
Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis (2009) 1.80
Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation (2004) 1.73
Bone, sweet bone--osteoporotic fractures in diabetes mellitus. Nat Rev Endocrinol (2012) 1.73
Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. Eur J Heart Fail (2011) 1.70
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67
Occurrence of late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail (2011) 1.63
Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res (2012) 1.58
Method for aortic wall strain measurement with three-dimensional ultrasound speckle tracking and fitted finite element analysis. Ann Thorac Surg (2013) 1.56
Heart rate variability in patients with cardiac hypertrophy--relation to left ventricular mass and etiology. Am Heart J (2006) 1.55
Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol (2002) 1.53
RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol (2002) 1.52
Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation (2003) 1.47
Chest pain in primary care: epidemiology and pre-work-up probabilities. Eur J Gen Pract (2009) 1.43
Isolated cardiac sarcoidosis associated with the expression of a splice variant coding for a truncated BTNL2 protein. Cardiology (2007) 1.42
Non-compaction cardiomyopathy in an adult with hereditary spherocytosis. Eur J Heart Fail (2006) 1.41
2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases. Rev Esp Cardiol (Engl Ed) (2015) 1.39
Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. PLoS Genet (2010) 1.37
Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab (2004) 1.35
Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun (2002) 1.35
Gorham-Stout disease--stabilization during bisphosphonate treatment. J Bone Miner Res (2004) 1.29
Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol (2009) 1.23
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood (2003) 1.22
miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol (2011) 1.15
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res (2003) 1.14
Accuracy of symptoms and signs for coronary heart disease assessed in primary care. Br J Gen Pract (2010) 1.13
Identification of mutational hot spots in LMNA encoding lamin A/C in patients with familial dilated cardiomyopathy. Basic Res Cardiol (2008) 1.12
The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant (2008) 1.11
Magnetic resonance imaging in pericardial diseases. Indications and diagnostic value. Herz (2006) 1.11
Bacterial pericarditis: diagnosis and management. Am J Cardiovasc Drugs (2005) 1.10
Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation (2003) 1.09
Preoperative and perioperative care for patients with suspected or established aortic stenosis facing noncardiac surgery. Chest (2005) 1.09
WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res (2012) 1.08
Accuracy of general practitioners' assessment of chest pain patients for coronary heart disease in primary care: cross-sectional study with follow-up. Croat Med J (2010) 1.05
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica (2013) 1.05
Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis (2005) 1.02
Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab (2004) 1.02
Gender differences in presentation and diagnosis of chest pain in primary care. BMC Fam Pract (2009) 1.01
Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. J Bone Miner Res (2009) 1.00
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol (2007) 1.00
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun (2005) 0.99
Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol (2003) 0.99
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol (2011) 0.98
Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab (2011) 0.98
VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery (2002) 0.98
Detection of Porphyromonas gingivalis DNA in aortic tissue by PCR. J Periodontol (2002) 0.98
The role of osteoclast-associated receptor in osteoimmunology. J Immunol (2011) 0.97
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett (2009) 0.97
Clinical and immunologic characteristics in peripartum cardiomyopathy. Int J Cardiol (2006) 0.97
Management strategies in pericardial emergencies. Herz (2006) 0.96
Activated nuclear transcription factor kappaB in patients with myocarditis and dilated cardiomyopathy--relation to inflammation and cardiac function. Biochem Biophys Res Commun (2005) 0.96
Right ventricular cardiac myxoma. Diagnostic usefulness of cardiac magnetic resonance imaging. Herz (2005) 0.95
A missense variant in desmoglein-2 predisposes to dilated cardiomyopathy. Mol Genet Metab (2008) 0.95
Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res (2008) 0.95
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz (2002) 0.94
Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res (2013) 0.94
Pericardial syndromes: an update after the ESC guidelines 2004. Heart Fail Rev (2013) 0.93
Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs. Int J Cardiol (2012) 0.93
Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone (2009) 0.93
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol (2012) 0.93
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem (2011) 0.93
Long-term cyclic strain downregulates endothelial Nox4. Antioxid Redox Signal (2009) 0.93
Parvovirus B19 genome in endomyocardial biopsy specimen. Circulation (2004) 0.93
Seizures associated with zoledronic acid for osteoporosis. J Clin Endocrinol Metab (2011) 0.92
Chest wall syndrome in primary care patients with chest pain: presentation, associated features and diagnosis. Fam Pract (2010) 0.92
A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J (2013) 0.92
Gender bias revisited: new insights on the differential management of chest pain. BMC Fam Pract (2011) 0.91
Regenerative potential of glycosaminoglycans for skin and bone. J Mol Med (Berl) (2011) 0.91
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 0.91
Novel point mutations in the mitochondrial DNA detected in patients with dilated cardiomyopathy by screening the whole mitochondrial genome. Biochem Biophys Res Commun (2004) 0.91
Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. Bone (2011) 0.90
Periodontal microbiota in patients with coronary artery disease measured by real-time polymerase chain reaction: a case-control study. J Periodontol (2007) 0.90